1665 Aurora CtAurora, CO 80045
Fax+1 720-848-0180
Overview of Dr. Lam
Elaine Lam, MD, is a medical oncology specialist with a subspecialty in genitourinary cancers. She completed her medical education at the University of Colorado School of Medicine Anschutz Medical Campus in 2003, followed by an internal medicine residency, and a fellowship in hematology and medical oncology. Dr. Lam is a Professor at the University of Colorado School of Medicine Anschutz Medical Campus. Her practice locations in include the University of Colorado Cancer Cancer in Aurora, CO and the CU Medicine Medical Oncology Clinic at Highlands Ranch Hospital. Her clinical expertise includes renal cell carcinoma, urothelial/bladder carcinoma, prostate cancer, and testicular cancer. She has contributed to numerous clinical trials and published research in esteemed journals such as The Lancet Oncology and The New England Journal of Medicine. Dr. Lam has been recognized as a Fellow of the American College of Physicians. She previously served on the National Comprehensive Cancer Network Kidney Cancer Panel. She is the Medical Director of Cancer Research at Highlands Ranch Hospital.
Education & Training
Ohio State University HospitalFellowship, Hematology and Medical Oncology, 2007 - 2010
University of ColoradoResidency, Internal Medicine, 2003 - 2006- University of Colorado School of Medicine Anschutz Medical CampusClass of 2003
Certifications & Licensure
CO State Medical License 1998 - 2027
WY State Medical License 2021 - 2027
OH State Medical License 2007 - 2012
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Fellow of the American College of Physicians American College of Physicians, 2018
- CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2012, 2014, 2016-2017
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory - Core EMR, Epic Systems Corporation, 2012, 2014, 2016-2017
Clinical Trials
- S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery Start of enrollment: 2011 Apr 01
- Study of TAK-228 In Patients With Previously Treated Metastatic Renal Cell Carcinoma Start of enrollment: 2017 Aug 01
- A Study Comparing Nivolumab, Nivolumab in Combination With Ipilimumab and Placebo in Participants With Localized Kidney Cancer Who Underwent Surgery to Remove Part of a Kidney Start of enrollment: 2017 Jul 07
Publications & Presentations
PubMed
- A Phase II Trial Using Grape Seed Extract for Prostate Cancer Patients With Nonmetastatic Prostate-Specific Antigen Progression After Local Therapy.Paul Maroni, Tad A Manalo, Hannah Baker, Elizabeth R Kessler, Andrew Nicklawsky
Molecular Carcinogenesis. 2026-09-27 - 1 citationsTyrosine kinase inhibitors affect sweet taste and dysregulate fate selection of specific taste bud cell subtypes via KIT inhibition.Christina M Piarowski, Jennifer K Scott, Courtney E Wilson, Heber I Lara, Ernesto Salcedo
Development. 2026-04-15 - 2 citationsDeterminants of pancreatic tropism in metastatic renal cell carcinoma.Haitao Xu, Payal Kapur, Alana Christie, Aleksandra W Nielsen, Averi Perny
JCI Insight. 2026-03-09
Press Mentions
‘She Cares’: A CU Department of Medicine Doctor Celebrates a Patient’s 100th BirthdayFebruary 29th, 2024- Some Cancer Drugs Disrupt Taste by Changing the Cells Inside Taste Buds, Study ShowsApril 22nd, 2026
Insurance Accepted
- Aetna Choice POS II
Aetna HMO
Anthem PPO
BCBS Blue Card PPO
CIGNA HMO
CIGNA Open Access
CIGNA PPO
First Health PPOGreat West PPO
HIP of New York - Select PPO
Humana ChoiceCare Network PPO
Multiplan PPO
Rocky Mountain Group/Indiv - HMO/Private Pay
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO - Please verify your coverage with the provider's office directly when scheduling an appointment
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: